Point in time view as at 03/12/2007.
The Medicines for Human Use (Clinical Trials) Regulations 2004, Paragraph 3 is up to date with all changes known to be in force on or before 15 March 2025. There are changes that may be brought into force at a future date. Changes that have been made appear in the content and are referenced with annotations.
3.—(1) For the purposes of this Schedule, a person gives informed consent to take part, or that a subject is to take part, in a clinical trial only if his decision—U.K.
(a)is given freely after that person is informed of the nature, significance, implications and risks of the trial; and
(b)either—
(i)is evidenced in writing, dated and signed, or otherwise marked, by that person so as to indicate his consent, or
(ii)if the person is unable to sign or to mark a document so as to indicate his consent, is given orally in the presence of at least one witness and recorded in writing.
(2) For the purposes of this Schedule, references to informed consent—
(a)shall be construed in accordance with paragraph (1); and
(b)include references to informed consent given or refused by an adult unable by virtue of physical or mental incapacity to give informed consent, prior to the onset of that incapacity.
All content is available under the Open Government Licence v3.0 except where otherwise stated. This site additionally contains content derived from EUR-Lex, reused under the terms of the Commission Decision 2011/833/EU on the reuse of documents from the EU institutions. For more information see the EUR-Lex public statement on re-use.
